To clarify findings of elevated cytokine levels in major depression (MD), this study aimed to investigate the relationship between serum levels of cytokines, symptoms of MD and antidepressant treatment outcome. At baseline (T0) and 4 weeks following initiation of antidepressant treatment (T1), levels of tumor necrosis factor (TNF)-α, interferon (IFN)-γ, interleukin (IL)-2, IL-4, IL-5, IL-10, IL-12, IL-13, granulocyte-macrophage-colony-stimulating-factor (GM-CSF), CRP and depression ratings HAMD-₁₇ and BDI-II were assessed in 30 patients with MD and 30 age-and sex-matched controls. At T0, in the patient group, cytokines, but not CRP, negatively correlated with individual BDI-II-items, factors and severities and showed both negative and positive correlations with HAMD-₁₇ items. At T1 and within the controls, no such relationships were observed. At T0 and T1, levels of both pro- and anti-inflammatory cytokines were significantly higher in treatment responders (ΔHAMD-₁₇T0-T1≥50%, n = 15) compared to non-responders. When controlled for baseline BDI, differences between groups were only found significant for IL-2 at T0. The results suggest cytokines are not generally pro-depressive but rather relate to more specific regulation of symptoms and severities in MD. Together with the association between cytokines and treatment responder status, these data support cytokines as a promising but still controversial biomarker of depression.

Item Type:	Refereed Article
Keywords:	antidepressant treatment prediction, BDI-II, biomarker, depressive symptoms, hAMD-17, immunity, inflammation
Research Division:	Health Sciences
Research Group:	Health services and systems
Research Field:	Mental health services
Objective Division:	Health
Objective Group:	Public health (excl. specific population health)
Objective Field:	Mental health
UTAS Author:	Kirkby, KC (Professor Kenneth Kirkby)
ID Code:	107344
Year Published:	2016
Web of Science® Times Cited:	48
Deposited By:	Medicine
Deposited On:	2016-03-11
Last Modified:	2022-08-25
Downloads:	0